A single-center phase I trial was performed using autologous T cells, modified to express a CD33-targeted CAR with 4-1BB and CD3 co-stimulatory domains co-expressed with a truncated human epidermal growth factor receptor for relapsed/refractory AML patients. This evidence concerns the gene CD33 and acute myeloid leukemia.